Skip to main content

Table 2 Exploratory endpoints (change from baseline after treatment) in FAS and PPS population

From: Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial

Exploratory endpoints Mean change from baseline (95% CI) in FAS population Mean change from baseline (95% CI) in PPS population
Oxygen group Hydrogen/oxygen group P value Oxygen group Hydrogen/oxygen group P value
Pulmonary function
 FVC 0.18 (0.07, 0.29) 0.10 (− 0.01,0.21) 0.309 0.19 (0.08, 0.31) 0.10 (− 0.01, 0.21) 0.250
 FEV1 0.12 (0.06, 0.19) 0.11 (0.04, 0.18) 0.769 0.13 (0.06, 0.19) 0.11 (0.03, 0.18) 0.698
 FEV1/FVC (%) 1.52 (− 0.40, 3.44) 2.45 (− 0.10, 4.99) 0.563 1.22 (− 0.83, 3.29) 2.29 (− 0.39, 4.97) 0.529
Arterial blood gas
 pH 0.001 (− 0.013, 0.014) 0.004 (− 0.009, 0.018) 0.700 0.001 (− 0.013, 0.016) 0.003 (− 0.010, 0.017) 0.875
 PaO2 (mmHg) − 0.45 (− 5.65, 4.75) 3.46 (− 5.77, 12.70) 0.461 1.39 (− 3.87, 6.65) 4.46 (− 5.74, 14.66) 0.592
 PaCO2 (mmHg) 0.71 (− 1.09, 2.51) − 1.09 (− 2.88, 0.71) 0.160 0.53 (− 1.42, 2.48) -0.55 (− 2.44, 1.34) 0.424
 HCO3 (mmol/L) 0.61 (− 0.39, 1.62) − 0.36 (− 1.20, 0.48) 0.136 0.56 (− 0.49, 1.61) − 0.14 (− 1.03, 0.76) 0.315
  1. FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, PaO2 arterial oxygen pressure, PaCO2 arterial carbon dioxide pressure, HCO3 bicarbonate, 95% CI 95% confidence interval, FAS full analysis set, PPS per-protocol set